

R Jeroen A Van Moorselaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3621350/publications.pdf>

Version: 2024-02-01

60
papers

1,191
citations

430754

18
h-index

414303

32
g-index

61
all docs

61
docs citations

61
times ranked

2142
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical outcomes and proposal for a treatment algorithm for urethral strictures in transgender men. <i>BJU International</i> , 2022, 129, 63-71.	1.3	5
2	Incidence of testicular cancer in trans women using gender-affirming hormonal treatment: a nationwide cohort study. <i>BJU International</i> , 2022, 129, 491-497.	1.3	7
3	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52.	0.9	3
4	Radiotherapy is the Preferred Primary Tumor Treatment in Oligometastatic Prostate Cancer. <i>European Urology Open Science</i> , 2022, 35, 70-71.	0.2	0
5	Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non-muscle-invasive Bladder Cancer. <i>European Urology Open Science</i> , 2022, 37, 7-13.	0.2	1
6	Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation. <i>Clinical Epigenetics</i> , 2022, 14, 19.	1.8	16
7	Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer. <i>BJU International</i> , 2022, 129, 768-776.	1.3	7
8	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Oncology</i> , 2021, 4, 618-627.	2.6	6
9	Patient reported outcome measures concerning urinary incontinence after robot assisted radical prostatectomy: development and validation of an online prediction model using clinical parameters, lower urinary tract symptoms and surgical experience. <i>Journal of Robotic Surgery</i> , 2021, 15, 593-602.	1.0	15
10	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	1.6	1
11	Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. <i>European Urology Oncology</i> , 2021, 4, 628-634.	2.6	46
12	Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. <i>European Urology Oncology</i> , 2021, 4, 821-825.	2.6	42
13	A systematic review on mutation markers for bladder cancer diagnosis in urine. <i>BJU International</i> , 2021, 127, 12-27.	1.3	14
14	Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up. <i>Abdominal Radiology</i> , 2021, 46, 373-379.	1.0	12
15	Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 340-349.	3.3	84
16	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2960-2969.	3.3	8
17	Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1100-1109.	0.2	4
18	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1108-1109.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1662-1662.	0.2	0
20	The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1655-1662.	0.2	10
21	Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for ¹⁸ F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 210-216.	2.8	10
22	Repeatability of Quantitative ¹⁸ F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1320-1325.	2.8	22
23	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e233-e253.	0.9	4
24	The First Experience of Using the Pedicled Labia Minora Flap for Urethral Lengthening in Transgender Men Undergoing Anterolateral Thigh and Superficial Circumflex Iliac Artery Perforator Flap Phalloplasty: A Multicenter Study on Clinical Outcomes. <i>Urology</i> , 2020, 138, 179-187.	0.5	13
25	Genital Gender-Affirming Surgery Without Urethral Lengthening in Transgender Men: A Clinical Follow-Up Study on the Surgical and Urological Outcomes and Patient Satisfaction. <i>Journal of Sexual Medicine</i> , 2020, 17, 2478-2487.	0.3	22
26	An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?. <i>Translational Andrology and Urology</i> , 2019, 8, S346-S347.	0.6	1
27	The Surgical Techniques and Outcomes of Secondary Phalloplasty After Metoidioplasty in Transgender Men: An International, Multi-Center Case Series. <i>Journal of Sexual Medicine</i> , 2019, 16, 1849-1859.	0.3	22
28	A two-gene methylation signature for the diagnosis of bladder cancer in urine. <i>Epigenomics</i> , 2019, 11, 337-347.	1.0	23
29	Objectifying grade in Ta-T1 urothelial carcinomas of the bladder using proliferative and quantitative markers: A multicentre study in 310 bladder tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 530.e1-530.e8.	0.8	4
30	Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 337-343.	2.0	3
31	Healthy Tissue Uptake of ⁶⁸ Ga-Prostate-Specific Membrane Antigen, ¹⁸ F-DCFPyL, ¹⁸ F-Fluoromethylcholine, and ¹⁸ F-Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1111-1117.	2.8	23
32	Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial. <i>Urologia Internationalis</i> , 2019, 102, 69-76.	0.6	3
33	The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review. <i>Epigenomics</i> , 2018, 10, 673-687.	1.0	24
34	Plasma FGF23 is not elevated in prostate cancer. <i>Clinica Chimica Acta</i> , 2018, 478, 129-131.	0.5	3
35	The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 571-575.	1.3	8
36	Prognostic Value of [¹⁸ F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 406-410.	0.4	11

#	ARTICLE	IF	CITATIONS
37	Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2018, 4, 694-701.	1.6	43
38	Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. <i>European Urology</i> , 2018, 73, 226-232.	0.9	95
39	An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 400.e7-400.e14.	0.8	13
40	Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e985-e992.	0.9	19
41	Confocal Laser Endomicroscopy and Optical Coherence Tomography for the Diagnosis of Prostate Cancer: A Needle-Based, In Vivo Feasibility Study Protocol (IDEAL Phase 2A). <i>JMIR Research Protocols</i> , 2018, 7, e132.	0.5	7
42	First-line non-cytotoxic therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials. <i>BJU International</i> , 2017, 119, 831-845.	1.3	14
43	Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e773-e782.	0.9	33
44	Case Presentation: Neurogenic Bladder in a Girl After Surgery for Cloacal Malformation. <i>European Urology Focus</i> , 2017, 3, 158-160.	1.6	0
45	Primary Treatment for Prostate Cancer in an Elderly Man. <i>European Urology Focus</i> , 2017, 3, 325-326.	1.6	0
46	Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials. <i>Seminars in Oncology</i> , 2017, 44, 358-371.	0.8	13
47	Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. <i>Oncotarget</i> , 2016, 7, 22566-22578.	0.8	113
48	Isolated Lung Metastases After Radical Nephrectomy for Clear Cell Carcinoma. <i>European Urology Focus</i> , 2016, 2, 577-578.	1.6	0
49	Case Presentation: Mycotic Aortic Aneurysm and Psoas Abscess as a Complication of Bacillus Calmette-Guérin Instillations. <i>European Urology Focus</i> , 2016, 2, 351-353.	1.6	5
50	Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?. <i>Familial Cancer</i> , 2016, 15, 297-300.	0.9	3
51	Repeatability of Quantitative ¹⁸ F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 721-727.	2.8	22
52	Percutaneous Needle Based Optical Coherence Tomography for the Differentiation of Renal Masses: a Pilot Cohort. <i>Journal of Urology</i> , 2016, 195, 1578-1585.	0.2	15
53	Quantification of ¹⁸ F-Fluorocholine Kinetics in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 365-371.	2.8	32
54	Prevalence of Birt-Hogg-Dub syndrome in patients with apparently primary spontaneous pneumothorax. <i>European Respiratory Journal</i> , 2015, 45, 1191-1194.	3.1	70

#	ARTICLE	IF	CITATIONS
55	A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems. <i>Molecular Imaging and Biology</i> , 2015, 17, 714-725.	1.3	10
56	Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 7-15.	0.8	18
57	Facial Fibrofolliculomas as Indicator for Renal Cell Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 609-610.	0.6	0
58	EAU Policy on Live Surgery Events. <i>European Urology</i> , 2014, 66, 87-97.	0.9	50
59	Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer. <i>Anticancer Research</i> , 2014, 34, 2689-700.	0.5	14
60	Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. <i>Journal of Extracellular Vesicles</i> , 2013, 2, .	5.5	125